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There is a growing interest from the scientific community in the appropriate use of cardiovascular imaging techniques for diagnosis and decision
making in Europe. To develop appropriateness criteria for cardiovascular imaging use in clinical practice in Europe, a dedicated taskforce has been
appointed by the European Society of Cardiology (ESC) and the European Association of Cardiovascular Imaging (EACVI). The present paper
describes the appropriateness criteria development process.
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Introduction
Cardiovascular imaging is characterized by continuously evolving
technology developments in all modalities and increasing diversifica-
tion of clinical indications for diagnosis, follow-up, and treatment of
disease.1 Use in clinical practice varies, mainly depending on local
availability of technology, expertise and funds and based on the clin-
ician’s choice. Assistance with decision making both regarding the
choice of imaging modality in a certain clinical scenario and regarding
the future development of availability at local, national, and European
level becomes essential. To provide this assistance, a dedicated
taskforce has been appointed by the European Society of Cardiology
(ESC) and the European Association of Cardiovascular Imaging
(EACVI) with the specific aim to define appropriateness criteria for
cardiovascular imaging use in clinical practice in Europe.
Definition
The appropriateness criteria will be evidence-, guidelines-, and best
practice-based criteria for the appropriate use of cardiovascular
imaging modalities in clinical practice.2 Their evidence-based charac-
ter implies periodic update to acknowledge new research findings.
Their guidelines-based character implies validity of appropriateness
criteria within the same boundaries as the respective guidelines
(for example, national appropriateness criteria based on national
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guidelines/European appropriateness criteria based on European
Guidelines). Their best practice-based character implies involvement
of experts and centres of excellence to complement existing
evidence and current guidelines.
The appropriateness criteria are not legal documents; they are
meant to assist decisionmaking rather than to strictly prescribe an ap-
proach.3 The criteria cannot be exhaustive; they only refer to certain
selected high impact clinical scenarios.
Background
The need to define appropriateness criteria for the use of diagnostic
modalities in clinical practicewas recognized over two decades ago in
the American healthcare system. Appropriateness criteria for the se-
lection, use, and reimbursement of an imaging test were developed in
response to demand from medical professionals, society, and regula-
tors. The first appropriateness criteria for the selection of an imaging
test in specific clinical conditions were developed by the American
College of Radiology, with aim to assist referring physicians with de-
cision making. Regarding cardiovascular imaging, appropriateness cri-
teria for the use of an imaging test encompassing various imaging
modalities, a range of clinical scenarios, and several clinical indications
were developed by the American College of Cardiology Foundation
(ACCF) Appropriate Use Criteria Taskforce in collaboration with
the American Heart Association as well as relevant societies and col-
leges for each modality. Appropriateness criteria were developed for
echocardiography,4 stress echocardiography,5 cardiac computed
tomography,6 cardiac magnetic resonance imaging,7 and cardiac
radionuclide imaging.8 Appropriateness of diagnostic imaging use in
clinical practice audit has been performed by Medicare (American
federal government insurance program)with the aim to restrict reim-
bursement to appropriate indications.
More recently, the ESC and the EACVI have recognized the need
to develop appropriateness criteria for the use of cardiovascular
imaging modalities in Europe.
Bringing on a better understanding of physiology, pathology,
disease progression, and effect of treatment, cardiovascular imaging
developments have been an important factor in the development
of cardiac care. Based on continuously growing evidence, cardio-
vascular imaging modalities play central roles in disease diagnosis,
follow-up, management planning, and in the guidance of intervention.
Nevertheless, cardiovascular imaging modalities are also prone to in-
appropriateusebecause their perceived lowriskdoesnot discourage
referrals, while a multitude of factors encourage them. Referrals for
imaging tests may be made by imaging cardiologists, but also by non-
imaging cardiologists, hospital general medicine physicians, primary
care doctors, and specialists from all medical and surgical fields. Inev-
itably, the background of knowledge of the referrer will vary. Avail-
ability of clear appropriateness criteria and guidance will be of
particular benefit to non-cardiology referrers. Not only will appro-
priateness criteria inform the referrer, but they will also support
the decision not to request a test without concerns that such a deci-
sion could be considered as negligence. Defensive medical practice
explains many imaging requests. Depriving patients of diagnostic
tests is perceived as a liability more than exposing patients to un-
necessary tests, particularly as referring for imaging tests often
matches patient’s expectations. Furthermore, patients may even
demandreferral for imaging tests. In caseof existenceorco-existence
of a private healthcare system, reimbursement may represent an
incentive for referring and performing unnecessary imaging tests.
Aims
The appropriateness criteriawill bedeveloped with theaim toensure
the bestuseof cardiovascular imagingdiagnostic resources for a given
individual, the rational use of cardiovascular imaging resources for all
individuals in need of diagnosis, the most efficient use of available
funds for society, and the judicious implementation of evolving tech-
nology and evidence in clinical practice.
The best use of cardiovascular imaging diagnostic resources for a
given individual implies a series of considerations. Both under-use
and over-use of diagnostic modalities and techniques should be
avoided. Under-use of imaging modalities may result in incomplete
or incorrect diagnosis. Over-use of imaging modalities and techni-
ques may expose individuals to unnecessary risk (for example, radi-
ation, contrast media, and stress agents) and may delay diagnosis
and/or treatment for the respective individuals and for other indivi-
duals waiting for the same test. Overutilization has been defined as
the use of diagnostic imaging procedures, where circumstances indi-
cate that they are unlikely to improve patient outcome. Timing is a
major consideration for diagnostic imaging; under conditions of
limited resources, the appropriate use of a test for a certain individual
may be delayed by inappropriate use of the respective test for
another individual. This second individual may have been well
served by an alternative test. The alternative use of cardiovascular
imaging modalities, with their advantages and disadvantages, should
be described by the appropriateness criteria. Risk vs. benefit consid-
erations should inform the choice of test. The ‘risk’ refers not only to
side effects (e.g. allergic reaction to contrast agents), but also to the
consequences of a false-positive or a false-negative test and to the ap-
propriate testdelaydue to an initially wrong test choice. For example,
a false-positive functional imaging test can result in exposure to un-
necessary coronary angiography in a patient with non-cardiac chest
pain. Also, a false-negative functional imaging test may lead to the in-
correct exclusion of coronary artery disease as the cause of a
patient’s symptoms, potentially depriving that patient of secondary
prevention and increasing the risk of events. Furthermore, invasive
coronary angiography and revascularization can be delayed by un-
necessary functional imaging in a patient with exertional angina re-
fractory to medical treatment. Finally, the inappropriate escalated
use of imaging can also be a source of potential ‘treatment cascades’.
The rational use of cardiovascular imaging resources for all indivi-
duals in need of diagnosis implies the use of resources for the appro-
priate patients avoiding delay due to inappropriate ‘wait list’, which
includes patients in no need for the respective test. It also implies
the planned development of availability to allow appropriate criteria-
based use of modalities.
The most efficient use of available funds for society implies selec-
tion of the most cost-effective test for a certain indication and use
only of necessary diagnostic tests. While discouraging inappropriate
expenses, appropriateness criteria encourage appropriate expenses
and not the under-use of diagnostic tests.
The judicious implementationof evolving technologyandevidence
in clinical practice is ensured by a dynamic character of the
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appropriateness criteria, with periodic updates. Systematic review
and critical appraisal of published spontaneous research will inform
this periodic update. Furthermore, answers to specific questions
will be sought through research planned and conducted at the
request of the taskforce. The planned research will aim to close
gaps in evidence regarding risks, benefits, and cost-effectiveness of
using a certain imaging modality in a certain clinical scenario.
Challenges
The development of appropriateness criteria will face process-
related challenges and challenges related to the existence of multiple
imaging modalities and multiple realities within Europe (countries/
health systems/local variations in availability).
The first challenge is to define the appropriateness of an imaging
test. The first attempts to determine appropriateness referred to
therapeutic procedures, which can be straightforward characterized
based on their therapeutic benefit.2 In the case of imaging tests, the
characterization is not straightforward; the benefit of performing
the test is more difficult to define and varies with the precise indica-
tion for the test. For example, the benefit of performing a functional
imaging test in coronary artery disease varies with the precise indica-
tion, which can be diagnosis, prognosis (risk stratification), or man-
agement guidance.
Characterizing an imaging test as appropriate is made even more
challenging by the existence of several alternative tests with slightly
different characteristics. For example, functional imaging tests have
different sensitivities, specificities, and negative and positive predict-
ive values in the assessmentof coronaryartery disease, being moreor
less appropriate for each precise indication. A test with a high nega-
tivepredictivevaluewould bemoreappropriate for risk stratification,
whereas a test with high sensitivity would me more appropriate for
diagnosis of disease. Certainly, if invasive investigation would be
rather avoided in a certain patient because of comorbidities, high spe-
cificity and not high sensitivity becomes more appropriate. In
between two tests with similar performance for a specific indication,
the more cost-effective test becomes appropriate. The performance
of an imaging test is influenced by equipment characteristics and ex-
pertise used to perform and report the test, making recommenda-
tions even more difficult to underpin and validate.
The ESC and the EACVI aim to encourage homogeneous standar-
dized cardiovascular diagnosis and management in Europe. Cardio-
vascular imaging plays a central role in diagnosis, management
planning, and the guidance of procedures. As such, cardiovascular
imaging is an important target for standardization with aim to
promote homogeneous care; the development of cardiovascular
imaging appropriateness criteria will serve this aim. The appropriate-
ness criteria will be patient-centred, encouraging similar approach in
similar clinical scenarios across Europe but from a realistic perspec-
tive, acknowledging the existence of variation in resources and po-
tential. As such, appropriateness criteria for both best practice and
alternative acceptable practice should be defined. Challenges facing
the taskforce in regard with the development of realistic appropriate-
ness criteria in this context are:
(i) Integration of knowledge regarding current local guidelines and
more so regarding current practice considered as excellent care
in each country, because determination of appropriateness
should mirror actual clinical care.
(ii) Understanding the impact of each particular healthcare system
(national or private provision of care and/or insurance system)
in clinical practice.
(iii) Assimilation of information regarding currently existent
resources, and material potential for developments.
Development process
The first appropriateness criteria development method was
described by a RAND Corporation and UCLA (University of Califor-
nia, Los Angeles) team for medical and surgical procedures.3 The
method was used by the American College of Radiology in the devel-
opment of the first appropriateness criteria for imaging. Method
adjustments to suit cardiovascular imaging appropriateness criteria
development were proposed by the ACCF.2 Individually rating
each cardiovascular imaging modality before selecting the appropri-
ate modality for each indication was proposed by the ACCF.
The ESC/EACVI taskforce intends to follow the development
process steps already described in the American literature, making
necessary adjustments for a diverse European reality but a
common European cardiovascular imaging association (Figure 1).
The determination of appropriateness criteria will start with the
appointment of a panel of reviewers consisting of experts in each car-
diovascular imaging modality and of a voting panel,2 which will also
include non-imaging cardiologists with expertise in fields of cardi-
ology highly dependent on imaging for diagnosis and management
planning (i.e. interventional cardiology and heart failure), general car-
diologists, and other stakeholder representatives (physicians referring
for imaging tests, healthcare services reimbursement system represen-
tatives, and other healthcare professionals). Associations, Working
Groups, and National Societies will be asked to recommend voting
panel members. The RAND and UCLA team described method
recommends a voting panel with a minimum of 7 and a maximum of
15 members,3 and the use of an interview-based selection process to
limit the numbers in the case of multiple candidates. In our case, the
panel composition and the number of panel members will be adjusted
to better represent the multinational heterogeneous European reality.
Because cardiovascular imaging appropriateness criteria cannotbe
defined exhaustively for every possible clinical scenario encountered
in cardiology, the ESC/EACVI taskforcewill have to select high impact
clinical scenarios. These clinical scenarios should be selected because
they have high incidence or prevalence, high morbidity or mortality,
high cost associated with diagnosis or management, or simply
because the definition of appropriateness criteria in these scenarios
is highly likely to make a significant difference to clinical practice.
Comprehensive explicit presentation of the clinical scenarios will
aim to ensure correct interpretation by the voting panel involved in
scoring appropriateness of tests for each indication.
Systematic critical review of existent evidence, best practice, and
current ESC guidelines and ESC/EACVI-related position papers and
recommendation documents will be performed by the panel of
experts for each selected high impact clinical scenario.9 –11 Evidence
tables and a review summary will be generated to inform the defin-
ition of cardiovascular imaging indications. The cardiovascular
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imaging indications will be defined based on imaging taskforce and
expert panel consensus during indications definition workshops.
The next step will be the appropriateness scoring of tests for the
selected cardiovascular imaging indications, based on anonymous
voting by panel members. Initial independent scoring will be followed
by panel discussion of results and by a final round of independent
scoring as previously proposed by RAND–UCLA and ACCF (modi-
fied Delphi method). During the panel discussion, each panel member
will have the opportunity to compare his or her own results with the
overall scoring and to ask for any needed clarifications. Disagreements
will be discussed with the solepurpose tovalidate them (to ensure that
they are not simply due to misunderstanding) and not to eliminate
them. The described 1–9 scoring system (Figure 2) will be used:
(i) Score 1–3 denotes an inappropriate test for the selected indi-
cation.
(ii) Score 4–6 denotes uncertain appropriateness, which means
that either more evidence is needed in this regard (taskforce
planned research will have to be conducted in this case, particu-
larly for indications with high incidence or prevalence) or
further clinical details are needed to determine the appropriate
test.
(iii) Score 7–9 denotes an appropriate test for the selected
indication.
The median score from the final round of voting will determine the
appropriateness score for a particular test. Regardless of their
median score, tests for which there is significant disagreement in
between panel members will be characterized as having uncertain ap-
propriateness. We could consider that disagreement exists when
more than three panel members score a test outside the median
score range, whereas agreement exists when no more than two
Figure 1: Appropriateness criteria development process.
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panel members score the test outside the median score range.
Complex statistical methods to define agreement and disagreement
have been described and will be used if necessary.
The final step will be the determination of cardiovascular imaging
appropriateness per clinical indication across modalities.9 This step
will not be necessary in situations where a single imaging modality
was rated as appropriate. In situations where more than one
imaging modality was rated as appropriate, cost-effectiveness, per-
formance, side effects, associated risks, and clinical outcomes will
be considered in the preferred modality selection process. Cost-
effectiveness will playan important role in the caseof high impact clin-
ical indications. The cost-effectiveness is determined not only by the
direct cost of the test, but also by the indirect cost resulting from the
need of a second test because of poor performance of the first test.
The EACVI multi-modality appropriateness criteria will be deter-
mined by group judgement of experts from all cardiovascular imaging
modalities in a Consensus Conference.3 The need for further robust
evidence in the multi-modality field is acknowledged; both rando-
mized studies to compare imaging modalities for a particular indica-
tion and studies of outcomes are necessary.
The appropriateness criteria will be updated at regular intervals.
This will typically follow a 3-year cycle, but earlier updates may
become necessary in case new relevant evidence or developments
become available.
Application of appropriate use
documents
The appropriateness criteria, statement papers, educational material
supporting clinical implementation, and all related documents will be
made available online and also actively distributed to the European
Commission, the European National Societies, Working Groups
and Associations, National HealthcareAuthorities, Healthcare Insur-
ances, Social Security Systems, and patients’ associations. It is
expected that the distribution will cascade from National level to
Local Healthcare Authorities, Healthcare Commissioning Groups,
and Hospital Managers.
To assist clinical decision making and the selection of an appropri-
ate imaging test for a certain indication, web-based tools and apps will
be developed. Appropriateness criteria-related education initiatives
will focus particularly on inappropriate indications, which will be
clearly and explicitly stated on web-based materials, apps, pocket
cards, and posters for use at the point of delivery (imaging laborator-
ies) and at the point of request (family doctors’ surgeries and hospital
outpatient clinics).
The appropriate use documents will inform and guide clinical prac-
tice, prioritization of workload in imaging laboratories, demand and
capacity planning, development of workforce, resources and local fa-
cilities, as well as funding and reimbursement of cardiovascular
imaging. Tests assigned ‘uncertain appropriateness’ should not be
excluded fromclinical use; recentlyevolvedapplicationsof cardiovas-
cular imaging or rare indications often fall into this category because
of limited supporting evidence.
The appropriate use documents will become an essential practical
tool and a strong argument in the hands of all cardiovascular imaging
stakeholders:
(i) Beneficiary (patients and referring physicians) for requesting or
not requesting tests.
(ii) Providers (performing physicians and departments) for accept-
ing or rejecting referrals.
(iii) Authority (Healthcare and Social Security Systems) for regula-
tion and financial rationalization.
Perspectives and future directions
The appropriateness criteria will be patient-centred, facilitating the
best use of cardiovascular imaging resources for an individual in
need of a test while at the same time encouraging the best use of ma-
terial resources for the entire society, structured development of
resources, efficient financial expenditure, and homogenization of
care across Europe.
Access to patient imaging records would improve the use of car-
diovascular imaging avoiding duplication of tests in between institu-
tions and unnecessary premature repetition of tests at follow-up.
Images and not only reports should be madeavailable, should be stan-
dardized, comparable, transferable, and compatible with reanalysis.
Currently, access to imaging file is restricted by governance policies,
by communication means limitations, and by the existenceof vendor-
specific imaging storage and analysis packages. Future taskforce ap-
propriateness documents will highlight these issues to alert National
Societies, Healthcare Authorities, and the industry.
Figure 2: Appropriateness scoring.
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It is envisaged that, in the future, questions based on clinical scen-
arios meant to assess appropriate selection of imaging tests and ap-
propriate exclusion of inappropriate tests will be introduced in
cardiovascular imaging modalities certification and accreditation
exams and also in cardiology, cardiac surgery, and general medicine
speciality exams. Moreover, it is envisaged that performed tests
appropriateness audit will be introduced as a laboratory accredit-
ation and reaccreditation requirement. Clinical practice audit may
suggest the need to restrict the right to request cardiovascular
imaging tests to cardiologists only or may justify broadening of the re-
ferral pull based on correct use of appropriate use algorithms. Fur-
thermore, justification of broadening of the referral pull may come
from an audit of performed tests appropriateness and of accepted
vs. rejected referrals, audit which may suggest that the imaging
specialist is a reliable gatekeeper.
The appropriateness criteria themselves will be subjected to audit
to determine their actual patient carebenefit and their actual financial
impact.12
Conclusion
Due to growing demand for diagnostic cardiovascular imaging, the
development of criteria which aid appropriate use and planning of
availability becomes essential. By establishing appropriateness cri-
teria, the ESC/EACVI Taskforce aims to safeguard the interest of
the patients, society, and the European Cardiovascular Imaging
Community while promoting homogeneous healthcare provision,
implementation of guidelines and of evidence.
Conflict of interest: none declared.
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